Conclusion of non-exclusive drug rebate agreement according to § 130a para. 8 SGB V via an open-house model for pharmaceuticals with the trade name Orylmyte (ATC V01AA03)
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No guaranteed minimum purchase quantities; actual demand depends on prescription and dispensing behavior, making revenu...
The buyer may terminate the open-house procedure early if exclusive rebate agreements are concluded, typically 8-12 mon...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Aug 2028
- Conclusion of non-exclusive rebate agreement for Orylmyte (ATC V01AA03) under § 130a(8) SGB V
- Supply of Orylmyte and parallel/reimports subject to rebate agreement
Show full summary
Non-exclusive rebate agreement for the pharmaceutical product Orylmyte (ATC V01AA03) under an open-house model with AOK PLUS. The agreement is open to all interested pharmaceutical entrepreneurs meeting conditions. No guaranteed volume, no exclusivity. The contract runs until 31 August 2028. First submission deadline 5 August 2026, with ongoing periodic deadlines.
Risks
No guaranteed minimum purchase quantities; actual demand depends on prescription and dispensing behavior, making revenu...
The buyer may terminate the open-house procedure early if exclusive rebate agreements are concluded, typically 8-12 mon...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in §4(18) AMG
- Must comply with EU Russia sanctions regulation (Art. 5k of Regulation 833/2014)
Eligibility
- Must not have exclusion grounds per §§123,124 GWB
Requirements may be incomplete.
Buyer
Location
Erfurt, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Conclusion of non-exclusive drug rebate agreement according to § 130a para. 8 SGB V via an open-house model for pharmaceuticals with the trade name Orylmyte (ATC V01AA03)
Non-exclusive rebate agreement for Orylmyte, open to all qualified pharmaceutical entrepreneurs, no guaranteed minimum quantities, performance in Dresden, Saxony/Thuringia.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 09 Jul 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 477816-2026
Documents (1)
Similar tenders
Poland – Furniture – DZP.242.306.2026 Sukcesywny zakup wyposażenia meblowego wraz z dostawą, montażem i ustawieniem w pomieszczeniach Uniwersyteckiego Szpitala Klinicznego we Wrocławiu
Greece – Installation of cable laying – Προμήθεια υλικών και πλήρης κατασκευή της εναέριας Γ.Μ. 400kV ΚΥΤ ΝΕΑΣ ΣΑΝΤΑΣ – ΚΥΤ ΦΙΛΙΠΠΩΝ
Germany – Installation of doors and windows and related components – Tischlerarbeiten - Innentüren DIN 18355
Czechia – Portable computers – OPST – Konektivita, HW, SW, vybavení středních škol v Ústeckém kraji – SPŠ ÚL, Resslova – Koncové prvky II.
Poland – Electricity, heating, solar and nuclear energy – Świecka Grupa Zakupowa. Dostawa energii elektrycznej w okresie od 01.01.2027r. do 31.12.2027r.
Croatia – Restructuring work – Izvođenje radova na rekonstrukciji i dogradnji Konjičkog centra
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No guaranteed minimum purchase quantities; actual demand depends on prescription and dispensing behavior, making revenu...
The buyer may terminate the open-house procedure early if exclusive rebate agreements are concluded, typically 8-12 mon...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications